iRhythm(US:IRTC) Globenewswire·2026-02-19 21:05Core Insights - iRhythm Holdings, Inc. reported strong financial results for Q4 and full year 2025, marking a transformational year with significant revenue growth and positive net income for the first time in its history [4][10]. Financial Highlights Fourth Quarter 2025 - Revenue increased by 27.1% to $208.9 million compared to $164.3 million in Q4 2024, driven by higher demand for Zio Services [5][8]. - Gross profit rose to $148.1 million, up from $115.1 million in Q4 2024, with a gross margin of 70.9%, an improvement from 70.0% [6][8]. - Net income for Q4 2025 was $5.6 million, a significant improvement from a net loss of $1.3 million in Q4 2024 [9][8]. - Adjusted EBITDA was $34.3 million, with an adjusted EBITDA margin of 16.4%, reflecting a $15.0 million increase compared to Q4 2024 [8]. Full Year 2025 - Total revenue for 2025 reached $747.1 million, a 26.2% increase from $591.8 million in 2024 [10][11]. - Gross profit for the year was $527.3 million, up from $407.5 million in 2024, with a gross margin of 70.6%, improving from 68.9% [11]. - The net loss for 2025 was $44.6 million, a $68.7 million improvement compared to a net loss of $113.3 million in 2024 [12][10]. - Free cash flow for 2025 was $34.5 million, marking the first year of positive free cash flow in the company's history [8]. Operational Highlights - The company emphasized the growing demand for Zio across various healthcare sectors, highlighting its ability to provide proactive, data-driven arrhythmia detection [4]. - iRhythm plans to scale its platform globally, advance its product roadmap, and enhance its predictive AI capabilities while maintaining financial discipline [4]. 2026 Guidance - For 2026, iRhythm expects revenue between $870 million and $880 million, with an adjusted EBITDA margin of 11.5% to 12.5%, indicating continued growth and operational efficiency [13].